Kornimate/medical-research-clean huggingface dataset:
cardiovascular and renal risk in spain

Conditions: Cardiovascular Disease

Summary: iberican is a multicenter, longitudinal and observational population-based study of patients daily attended in primary care setting in spain. this study is aimed to determine the prevalence and incidence of cardiovascular risk factors in adult population in spain. patients will be followed-up for a minimum period of 5 years, every 6 months or a lesser period when clinically required. it has been estimated that a total of 15,000 individuals will be included.

iberican (identificación de la población española de riesgo cardio vascular y renal) is a multicenter, longitudinal and observational population-based study of patients daily attended in primary care setting in spain. the aims of iberican are to determine the prevalence and incidence of cardiovascular risk factors in adult population in spain. moreover, the development of cardiovascular outcomes, and risk factors control rates will be also analyzed. in iberican, subjects irrespective of the presence of risk factors or cardiovascular disease throughout spain will be included. no specific recommendations will be provide to physicians about treatments. as a result, treatments of patients will be prescribed, modified or withdrawn according only to physicians´ judgment. the study has been approved by the ethic committee of hospital carlos iii, madrid on february 2013. before inclusion, every patient will provide a written informed consent. patients will be followed-up for a minimum period of 5 years, every 6 months or a lesser period when clinically required. excepting a blood analysis in the previous 6 months before the inclusion, no other specific diagnostic tool or technique will be required for being included in the study. all blood and urine analysis or other techniques will be performed according to clinical practice during the follow-up. it has been estimated that a total of 15,000 individuals will be included.

Eligibility criteria:
inclusion criteria: * national health care system user. * resident at spain in the last 5 years. * attended by investigator in primary care setting. exclusion criteria: * change of regular residence to other city or country in the following 6 months. * life expectancy less than 5 years. * difficult to follow-up.

Keywords: cardiovascular disease hypertension diabetes smoking hypercholesterolemia cardiovascular risk factor
bariatric procedures and changes in incretins and gastric emptying

Conditions: Morbid Obesity

Summary: the study evaluates the gastric emptying by scintigraphy in patients that had bariatric surgery (rygb of gastric sleeve) comparing patients with successful and unsuccessful weight loss and in patients before and after the placement of a duodenal-jejunal bypass liner. additional, after bariatric surgery gut hormones that influence the gastric emptying rate are determined.

bariatric surgery reduces stomach volume and passage of foods through the gastrointestinal tract is altered. the satiety level often increases, which is probably caused by gut hormones. patients response on different bariatric procedures varies widely and it is difficult to predict which patient responds well. possibly, patients who have successful excess weight loss (ewl) two years after surgery have different gastric emptying rates compared to unsuccessful patients. changes in gut hormones after implantation of a duodenal-jejunal bypass liner were demonstrated in other studies. however, gastric emptying before and after placement of this liner is unknown.

Eligibility criteria:
inclusion criteria: * patients must be able to adhere to the study visit schedule and protocol requirements * patients must be able to give informed consent and the consent must be obtained prior to any study procedures * patients who had a follow-up period up till 2 years after bariatric surgery without any complications or * patients are eligible for djbl implantation exclusion criteria: * binge-eating or associated eating disorder * active drug or alcohol addiction * pregnancy or giving breast feeding * gluten allergy * inability to stop medication that affects the motility of the upper gi tract (anti-cholinergic drugs, prokinetics, theophylline, calcium blocking agents, opioids) * endocrine disease influencing gastric emptying (diabetes mellitus, hyper- or hypothyroidism). type 2 diabetes mellitus is not an exclusion criterium for patients receiving the djbl.
early intervention to promote cardiovascular health of mothers and children (enrich)

Conditions: Cardiovascular Diseases; Infant ALL; Maternal Behavior; Childhood Obesity

Summary: this pilot study aims to examine the feasibility and acceptability of adding a cardiovascular health module to the existing nurse family partnership (nfp) home visitation program delivered by trained nurses in the northern appalachian region of central pennsylvania.

the promoting cardiovascular health of northern appalachian mother-infant dyads: pilot study is a single arm pilot study that will enroll women with infants (\<1 month of age) participating in the nfp home visitation program in the northern appalachian region of central pennsylvania. this pilot study will include an enhanced version of the nfp standard care plan delivered by trained nurses to promote cardiovascular health by targeting soothing, feeding, sleep, and physical activity behaviors during infancy. the intervention delivered by trained visiting nurses will include behavior change strategies (e.g., goal setting, problem solving barriers). this pilot study will also examine the feasibility and acceptability of a digital device (actigraphy) during this same time period.

Eligibility criteria:
inclusion criteria: 1. mother-infant dyad enrolled in and receiving the nurse family partnership program through one of the study teams community partner offices throughout central pennsylvania 2. mother age ≥ 18 years at time of delivery 3. mother english speaking 4. singleton infant born at ≥ 35 weeks' gestation 5. infant age \< 1 month at time of consent 6. mother with reliable access to the internet for consent and data collection purposes exclusion criteria: 1. unable or unwilling to comply with the study visits and procedures. 2. participation in a concurrent intervention study. 3. infants with known chromosomal abnormalities, complex congenital heart disease, or birth defects inconsistent with survival to age 2 years. 4. infant with substantial feeding difficulty (e.g., those requiring tube feeding)
psychosocial effects of coloring in preeclamptic pregnant women

Conditions: Preeclampsia; Anxiety; Pregnancy; Stress

Summary: preeclampsia is one of the major causes of maternal and neonatal mortality and morbidity, affecting approximately 3-5% of pregnancies. a diagnosis of preeclampsia may lead to psychological problems such as psychosocial distress, depression, and anxiety due to prolonged hospitalization, concerns about the future health of the baby, separation from family, and adapting to a foreign environment. health professionals play a crucial role in the diagnosis, treatment, and care of high-risk pregnancies and also implement non-pharmacological supportive methods such as yoga, progressive muscle relaxation, and mindfulness. one of these non-pharmacological methods is mandala. according to the literature, integrating mandala coloring into perinatal care is believed to have beneficial effects. therefore, the primary aim of this study is to investigate the effects of mother-baby themed coloring on anxiety. the secondary aim is to determine its effects on psychosocial health and cortisol levels. h1a: is there a difference between anxiety scores in preeclamptic pregnant women who were and were not exposed to dyeing activity? h1b: is there a difference between psychosocial health scores in preeclamptic pregnant women who were and were not exposed to dyeing activity? h1c: is there a difference between cortisol levels in preeclamptic pregnant women who were and were not exposed to dyeing activity?


Eligibility criteria:
inclusion criteria: * having a single and healthy fetus * gestational age ≥ 20 weeks * diagnosed with preeclampsia by a physician * not having a history of treated pregnancy exclusion criteria: * using psychiatric medication (self-report) * receiving psychological counseling during the intervention * diagnosed with severe preeclampsia

Keywords: preeclampsia anxiety pregnancy mandala stress cortisol
firm as a stand-alone procedure in the treatment of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the firm study oslo will in two sequential within-patient trials investigate the efficacy of focal impulse and rotor modulation (firm) as a stand-alone procedure in the treatment of paroxysmal and persistent atrial fibrillation, evaluated by continuous pre- and post-procedural heart rhythm monitoring.

after a pilot/implementation study consisting of 10 patients with paroxysmal atrial fibrillation (af); 20 patients with paroxysmal af will be included in a within-patient trial. this study will be followed by a similar comparison in 20 patients with persistent or longstanding persistent af. the af driving sources will be visualized by a novel sequential bi-atrial panoramic contact mapping technique. unipolar signals will be recorded by a 64-polar basket catheter (firmap®, topera. inc.), then processed and the activation patterns visualized (rhythmview® 3d electrophysiologic mapping system, topera, inc.). focal impulse and rotor modulation (firm) will then be performed with standard irrigated radio frequency catheter ablation until rotor or focal impulse elimination is confirmed by repeat firm mapping. treatment efficacy will be assessed with continuous heart rhythm monitors (reveal xt®, medtronic, minneapolis, usa) implanted 3 months prior to ablation, and freedom from af defined as af burden \<1% at follow-up at 12, 24 and 30 months.

Eligibility criteria:
inclusion criteria: * paroxysmal atrial fibrillation despite of at least one class i or class iii antiarrhythmic drug and/or previous conventional ablation (pulmonary vein isolation). * at least one episode of paroxysmal atrial fibrillation should be documented by rhythm strip, ecg or implanted monitor during the last 6 months prior to ablation. exclusion criteria: * significant structural heart disease (including symptomatic coronary heart disease; prosthetic mitral or tricuspid valve; congenital heart disease where abnormality or its correction prohibits or increases the risk of ablation). * intracardiac thrombus, tumor or dense contrast on tee. * contraindication to anticoagulant therapy (heparin, warfarin, dabigatran and rivaroxaban). * anaphylactic allergy to contrast media. * poor general health resulting from other disease. * inability or refusal to provide written informed consent for the study.

Keywords: atrial fibrillation arrhythmias, cardiac heart diseases cardiovascular diseases pathological processes
comparison of biannual ultrasonography and annual unenhanced magnetic resonance imaging for hcc surveillance

Conditions: Cirrhosis; Hepatocellular Carcinoma

Summary: the purpose of this study is to investigate clinical feasibility of annual non-contrast magnetic resonance imaging for surveillance of hepatocellular carcinoma in high-risk group, in comparison with biannual ultrasonography.

the purpose of this study is to investigate clinical feasibility of annual non-contrast magnetic resonance imaging for surveillance of hepatocellular carcinoma in high-risk group, in comparison with biannual ultrasonography. in addition, the relationship between non-contrast mr parameters and clinical manifestation of liver function is investigated.

Eligibility criteria:
inclusion criteria: * equal to or older than 40 years * under surveillance using biannual ultrasonography (usg) and presence of liver usg within 6 months (+/- 1month) * risk index is equal to or higher than 2.33 (risk index = 1.65 (if the prothrombin activity is \<=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is \<=100x10(3)/mm3) + 0.74 (if the presence of hcv or hbsag is positive)). * signed informed consent exclusion criteria: * under 40 years * history of hcc * patients with pregnancy or nursing * any contraindication of mri * any contraindication of ct

Keywords: mri hcc surveillance
stereotactic radiotherapy with different fractionation modes for the early lung cancer

Conditions: Lung Cancer; Radiotherapy; Stereotactic Body Radiotherapy; Fractionation

Summary: the goal of this observational study is to study the efficacy and safety of stereotactic body radiotherapy (sbrt) with different fractionation modes for early lung cancer. the main questions it aims to answer are: how effective are different regimens of sbrt for early lung cancer? how safe are different regimens of sbrt of sbrt for early lung cancer?

the goal of this observational study is to study the efficacy and safety of stereotactic body radiotherapy (sbrt) with different fractionation modes for early lung cancer.. this study intends to review the patients with early lung cancer receiving sbrt of 30gy/1f or 36gy/3f from 2018 to 2024 in our center.

Eligibility criteria:
inclusion criteria: 1. signed written informed consent; 2. male or female aged ≥ 18 years and ≤ 75 years; 3. patients with early lung cancer confirmed by pathology or clinical multidisciplinary team (mdt); 4. the ecog ps was 0 to 1; 5. survival time ≥3 months; 6. laboratory results during screening must meet the following requirements: 1. blood routine: neutrophil absolute count (anc) ≥ 1.5 × 109/l, platelet count (plt) ≥ 100 × 109/l, hemoglobin (hgb) ≥ 90 g/l (no blood transfusion or erythropoietin dependence within 7 days); 2. liver function: total bilirubin (tbil) ≤ 1.5 times the upper limit of normal value (uln); alanine aminotransferase (alt) and aspartate aminotransferase (ast) were less than 2.5 times uln in subjects without liver metastasis, and alt and ast were less than 5 times uln in subjects with liver metastasis. 3. renal function: serum creatinine (cr) ≤1.5 times uln or cr clearance ≥60 ml/min (cockcroft-gault formula), and urine protein (upro) \&lt on routine urine test; 2+ or 24 h urinary protein quantification \&lt; 1g; 4. international standardized ratio (inr) ≤1.5 times uln and partial prothrombin time (ptt) or activated partial thrombin time (aptt) ≤1.5 times uln during the 7 days prior to treatment; exclusion criteria: 1. any unstable systemic disease, including but not limited to active infection, congestive heart failure \[new york heart association (nyha) class ≥ ii\], severe arrhythmia requiring medical therapy, liver, kidney, or metabolic disease; type i and type ii respiratory failure; 2. other malignancies within 5 years before randomization, except adequately treated cervical carcinoma in situ, basal cell or squamous skin cancer, local prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery, or papillary thyroid cancer;

Keywords: lung cancer stereotactic body radiotherapy fractionation
polytrauma and resuscitation impact on innate immunity

Conditions: Wounds and Injuries

Summary: major trauma can lead to a dysregulated response to secondary infection. severe injuries are accompanied by pro- and antiinflammatory changes that affect both adaptive and innate immunity. in this study we aim to assess cellular immuno-competence early during treatment in an attempt to identify signs of immuno-suppression.

polytrauma represents one of the most challenging critical conditions for caretakers worldwide and involves multiple damages of different anatomical regions. severe traumatic injuries are among the primary causes of death among young people under the age of 45 and half of them are due to uncontrollable bleeding. in the acute injury phase of trauma, severe blood loss is often accompanied by biochemical, cellular and physiological dysfunctions leading to an inflammatory response, infections and in some cases coagulopathy. we aim to identify immuno-suppression by analyzing phagocytic capacity, leukocyte subsets, surface molecule expression and extracellular vesicles in the peripheral blood of severly injured patients.

Eligibility criteria:
inclusion criteria: * age \> 18 * injury severity score (iss) \> 15 * incident to admission time \< 3h exclusion criteria: * preexisting condition * pregnancy or breastfeeding * diabetes * coronary heart disease * intake of antiphlogistic medication * neoplasm
public awareness and understanding of pc in the uae

Conditions: Palliative Care

Summary: palliative care (pc) is essential medical care for improving the quality of life for patients with life-threatening illnesses and their families. there has been substantial evolution of pc services in the united arab emirates (uae), yet public awareness regarding pc remains shallow, hindering its utilization and acceptance on a large scale.

this study aimed to evaluate public perceptions and awareness of pc in the uae. a cross-sectional survey was conducted in both arabic and english. this study emphasizes the need of addressing these gaps to integrate pc effectively into the uae healthcare system, ensuring equitable access and improved quality of life for patients and their families.

Eligibility criteria:
inclusion criteria: * uae residents * provided informed consent to participate * completed the survey in either arabic or english exclusion criteria: * non-uae residents * incomplete survey responses (if applicable)

Keywords: supportive care
rehabilitation of everyday memory impairment in parkinson disease: a pilot study

Conditions: Parkinson's Disease

Summary: cognitive impairment is common among non-demented individuals with parkinson disease (pd) and is a significant source of disability and reduced quality of life. unfortunately, there are no successful interventions to address these impairments. prospective memory impairment is a particularly functionally- and clinically-relevant problem in pd. the investigator's project will determine if a targeted intervention strategy improves pd participants' prospective memory. the investigator's goal is to improve pd patients' everyday prospective memory so they can successfully perform desired activities and roles.

cognitive impairment is common among non-demented individuals with parkinson disease (pd) and is a significant source of disability and reduced quality of life. unfortunately, there are no successful interventions to address these impairments. prospective memory impairment is a particularly functionally- and clinically-relevant problem in pd. the investigator's project will determine if a targeted intervention strategy improves pd participants' prospective memory. the investigator will use a randomized controlled design and a laboratory-based assessment of prospective memory to test the effect of the strategy in a controlled environment. the investigator will also see if pd participants, with support from an occupational therapist (ot), can generalize the strategy to their complex, real-world environments and tasks. our goal is to improve pd patients' everyday prospective memory so they can successfully perform desired activities and roles.

Eligibility criteria:
inclusion criteria: * participants will be males and females over age 50 who meet criteria for idiopathic typical pd, are hoehn \& yahr39 stage i-iii (mild-moderate disease) and are treated with levodopa/carbidopa. exclusion criteria: * possible dementia, * treatment with certain medications that interfere with cognition (e.g., anticholinergics), * change in medications over the study period, other neurological disorders, brain surgery (e.g., stn dbs), * history of psychotic disorder or significant current psychiatric disorder, or any condition that would interfere with testing (e.g., vision problems).
a study to asses effectiveness and treatment management of oral venetoclax tablets + subcutaneously injected azacitidine in adult participants ineligible for intensive chemotherapy with de novo acute myeloid leukemia (aml) in italy

Conditions: Acute Myeloid Leukemia

Summary: acute myeloid leukemia (aml) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. this study will evaluate how well venetoclax in combination with azacitidine works to treat aml in newly diagnosed adult participants who are ineligible for intensive chemotherapy in italy. venetoclax in combination with azacitidine is approved in italy to treat acute myeloid leukemia (aml) in newly diagnosed adults who are ineligible for intensive chemotherapy. all study participants will receive venetoclax in combination with azacitidine as prescribed by their study doctor in accordance with approved local label. adult participants with a new diagnosis of aml will be enrolled. around 150 participants will be enrolled in the study at approximately 20-25 sites in italy. participants will receive venetoclax tablets to be taken by mouth in combination with azacitidine given by subcutaneous (sc) injection according to the approved local label. the duration of the study is approximately 18 months. there is expected to be no additional burden for participants in this trial. all study visits will occur during routine clinical practice and participants will be followed for 18 months.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of primary or secondary acute myeloid leukemia (aml), deemed ineligible for intensive induction chemotherapy because of age, performance status, comorbidities or any other clinical reason as defined by the treating physician. * investigator decision on patient treatment with venetoclax + azacitidine must have been reached prior to and independently of recruitment in the study. * treatment prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies. exclusion criteria: * participants affected by acute promyelocytic leukemia. * prior treatment for aml, excluding hydroxyurea. * participation in a clinical trial of an investigational drug, concurrently or within the last 30 days. participation in another post-marketing observational study or registry is acceptable

Keywords: acute myeloid leukemia venetoclax venclexta venclyxto azacitidine abt-199 cancer
diet, exercise and body fat in 3-5 year olds

Conditions: Healthy

Summary: to determine how practical and precise different body composition methods are for measuring body fat and lean tissue in young children and to determine if certain dietary factors and physical activity patterns are related to body fat in children.


Eligibility criteria:
inclusion criteria: * 3-5 year old children * full term at birth * english as primary language * weighed at least 5.5# at birth * parent or guardian is at least 18 years of age exclusion criteria: * child has any chronic condition, metabolic disorder, pulmonary disorder, bone disorder, condition that may affect growth, add or adhd * child on any medication thought to interfere with study parameters as determined by the investigator

Keywords: children nutrition body fat physical activity diet childhood obesity healthy children